Participate in effective shift crossovers.Īccurately complete documentation to ensure acceptable quality records. Maintain a clean & orderly work environment.Įscalate issues to supervisor, mechanic, or engineer. Work closely with other manufacturing support areas to coordinate activities. Work closely with maintenance/engineering to minimize equipment downtime. Utilize inspection tools, including visual inspection, to assess product quality.Īdhere to all approved and documented processes. Operate manufacturing machinery in PKG Manufacturing. Work Schedule: "Firemen's Rotation": Two 12 hour days (6:00am-6:00pm) followed by two 12 hour nights (6:00pm-6:00am) This position is located in Rochester, NY. Accountable for adhering to all EHS guidelines. This position is responsible for quality and maintaining the highest standards in compliance within company policies, procedures and all applicable regulations. Join us in our mission to transform the power of diagnostics into a healthier future for all.Īs we continue to grow as QuidelOrtho, we are seeking an Operator II, Packaging Manufacturing in the Slide Assembly Department. We strive to build meaningful connections with each other as we believe that employee happiness and business success are linked. Our culture puts our team members first and prioritizes actions that support happiness, inspiration and engagement. We are more than 6,000 strong and do business in over 130 countries, providing answers with fast, accurate and consistent testing where and when they are needed most - home to hospital, lab to clinic. “Together, we will continue to advance life-changing diagnostic solutions to improve patient outcomes and deliver economic benefits to the healthcare system.QuidelOrtho unites the strengths of Quidel Corporation and Ortho Clinical Diagnostics, creating a world-leading in vitro diagnostics company with award-winning expertise in immunoassay and molecular testing, clinical chemistry and transfusion medicine. By bringing together Quidel’s point-of-care diagnostics with Ortho’s vast global reach, there is a substantial opportunity to capitalize on the cross-selling opportunities, move into attractive adjacent markets, and accelerate innovative product expansion and the development of molecular technologies,” says Chris Smith, chairman and chief executive officer of Ortho. “Quidel shares our commitment to customers and passion for the patients we serve. With complementary areas of focus, the combined company will also operate with global reach and scale, maintaining the speed and agility that is fundamental to enhance Quidel’s current strategic approach. Further, the combined company will be poised to meet patient testing needs at all points of the care continuum-reference labs, hospitals, physicians’ offices, urgent care centers and at-home/retail locations. The combined organization will unite the companies’ technologies and platforms to benefit customers with expanded access to clinical chemistry, immunoassay, molecular diagnostics, immunohematology, donor screening, and point-of-care diagnostics offerings, according to the companies. We look forward to joining together to continue the strong patient focus that is core to our mission, creating an organization with a shared goal of discovering, developing, and delivering innovative solutions to our customers.” We are impressed by what Ortho has accomplished for patients. Importantly, our complementary cultures are underpinned by a commitment to our customers, patients, and the communities we serve, reinforcing our confidence in the long-term value creation of this transaction. “Establishing a stronger leadership position, we expect the combined company will emerge as a global player with top-tier R&D capabilities, a more diverse product pipeline, and broader geographic footprint. “The combination with Ortho will help solidify Quidel as a leader in the diagnostics industry, bringing together innovative, complementary products, solutions, and services that enhance the health and well-being of patients across the globe,” says Douglas Bryant, president and chief executive officer of Quidel, who will serve as chairman and chief executive officer of the combined company. The transaction is expected to close during the first half of fiscal year 2022, subject to customary closing conditions. Quidel Corporation and Ortho Clinical Diagnostics Holdings plc have entered into a definitive agreement in which Quidel will acquire Ortho, an in vitro diagnostics companies, for $24.68 per share of common stock using a combination of cash and newly issued shares in the combined company, representing a 25% premium over Ortho’s closing price on December 22, 2021, and an equity value of approximately $6.0 billion.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |